N/A
Manufactured by Hikma Pharmaceuticals USA Inc.
1,553 FDA adverse event reports analyzed
Last updated: 2026-04-15
ALLOPURINOL SODIUM is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Hikma Pharmaceuticals USA Inc.. The most commonly reported adverse reactions for ALLOPURINOL SODIUM include DRUG INEFFECTIVE, DYSPNOEA, PYREXIA, OFF LABEL USE, DIARRHOEA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for ALLOPURINOL SODIUM.
Out of 516 classified reports for ALLOPURINOL SODIUM:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 1,553 FDA FAERS reports that mention ALLOPURINOL SODIUM. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, DYSPNOEA, PYREXIA, OFF LABEL USE, DIARRHOEA, FATIGUE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Hikma Pharmaceuticals USA Inc. in connection with ALLOPURINOL SODIUM. Always verify the specific product and NDC with your pharmacist.